Savella® (milnacipran)
Effective 11/26/18

Plan	☒ MassHealth ☒Commercial/Exchange	**Program Type**	☒ Prior Authorization ☐ Quantity Limit ☐ Step Therapy
Benefit	☒ Pharmacy Benefit ☐ Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	**Specialty Medications** All Plans | Phone: 866-814-5506 | Fax: 866-249-6155 **Non-Specialty Medications** MassHealth | Phone: 877-433-7643 | Fax: 866-255-7569 Commercial | Phone: 800-294-5979 | Fax: 888-836-0730 Exchange | Phone: 855-582-2022 | Fax: 855-245-2134 **Medical Specialty Medications (NLX)** All Plans | Phone: 844-345-2803 | Fax: 844-851-0882		
Exceptions	N/A		

Overview
Savella® is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia.

Coverage Guidelines
Authorization may be granted for members with a diagnosis of fibromyalgia who has been started and stabilized on Savella for at least 30 days excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members with a diagnosis of fibromyalgia when ALL the following criteria are met:

1. Member has had a documented side effect, allergy, or treatment failure with an SNRI such as a generic venlafaxine product (Effexor® XR caps/tabs, etc.), duloxetine (Cymbalta®), or a desvenlafaxine product [Pristiq®, Khedezla®, etc.]).
2. Member has had a documented side effect, allergy, or treatment failure with at least one agent from two different categories including:
    a. Tricyclic antidepressants (e.g., amitriptyline, doxepin, desipramine, imipramine, etc.)
    b. SSRI's (e.g., citalopram, fluoxetine, paroxetine, sertraline, etc.)
    c. Cyclobenzaprine
    d. Gabapentin

Limitations
1. Initial approvals will be granted for 36 months.
2. Titration packs are approvable one-time only.

References

1. Clauw DJ., Mease P., Palmer RH., Gendreau RM., Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics. 2008; 30(11):1988-2004.
2. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009; 36:398-409.
3. Peterson EL. Fibromyalgia--management of a misunderstood disorder. J Am Acad Nurse Pract. 2007 Jul;19(7):341-8.
4. Chakrabarty S, Zoorob R. Fibromyalgia. Am Fam Physician. 2007 Jul 15;76(2):247-54.
5. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA.2004; 292(19):2388-2395.
6. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence- based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008; 67:536-541.
7. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol Clin Exp. 2004; 19: S27-S35.
8. Savella (milnacipran) [prescribing information]. Irvine, CA: Allergan USA Inc; December 2017
9. Buckhardt CS et al. Guideline for the management of fibromyalgia syndrome pain in adults and children. Glenview (IL): American Pain Society (APS); 2005. 109p (Clinical practice guideline; no. 4).
10. Traynor LM, Thiessen CN, Traynor AP. Pharmacotherapy of fibromyalgia. Am J Health-Syst Pharm. 2011;68(July 15, 2011):1307-1319.
11. Arnold LM, Palmer RH, Ma Y. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clinical Journal of Pain. 2013;29(12):1021-8.
12. Sumpton JE, Moulin DE. Fibromyalgia. Handbook of Clinical Neurology. 2014; 119:513-27.

Review History

11/22/10 – Reviewed
11/28/11 – Reviewed and updated
11/26/12 – Reviewed
11/25/13 – Reviewed and updated
08/04/14 – Updated (duloxetine generic; 12/30/13 file)
11/24/14 – Reviewed and updated in P&T Meeting
11/27/17 – Reviewed
11/26/18 – Reviewed in P&T Meeting

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.